Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD)

ClinicalTrials.gov ID: NCT01410227

Public ClinicalTrials.gov record NCT01410227. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 21, 2026, 6:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3 Clinical Study to Determine the Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor : Recombinant Factor VIII (rVWF:rFVIII) and rVWF in the Treatment of Bleeding Episodes in Subjects Diagnosed With Von Willebrand Disease

Study identification

NCT ID: NCT01410227
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Baxalta now part of Shire; Industry
Enrollment: 49 participants

Conditions and interventions

Conditions

Von Willebrand Disease

Interventions

Recombinant von Willebrand factor (rVWF) Biological
Placebo Drug
Recombinant factor VIIII (rFVIII) Biological

Biological · Drug

Eligibility (public fields only)

Age range: 18 Years to 65 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 31, 2011
Primary completion: Jan 31, 2014
Completion: Jan 31, 2014
Last update posted: May 18, 2021

2011 – 2014

United States locations

U.S. sites: 10
U.S. states: 9
U.S. cities: 10

Facility	City	State	ZIP	Site status
University of California Davis Cancer Center	Sacramento	California	95817	—
University of Miami Miller School of Medicine	Miami	Florida	33101	—
University of Illinois College of Medicine at Peoria	Peoria	Illinois	61614	—
Indiana Hemophilia and Thrombosis Center	Indianapolis	Indiana	46260	—
Newark Beth Israel Medical Center	Newark	New Jersey	07112	—
The Mary M Gooley Hemophilia Center and Rochester General Hospital	Rochester	New York	14621	—
University of North Carolina at Chapel Hill	Chapel Hill	North Carolina	27599	—
Pennsylvania Hospital	Philadelphia	Pennsylvania	19104	—
Hemophilia Center of Western Pennsylvania	Pittsburgh	Pennsylvania	15213	—
Blood Center of Wisconsin	Milwaukee	Wisconsin	53226	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 42 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01410227, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 18, 2021 · Synced Jul 21, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01410227 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →